01—Abstract
Summary
Summary of the 10-K filed February 13, 2018. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. reported its first year of INGREZZA (valbenazine) commercial sales in its annual report for fiscal 2017.
INGREZZA was approved by the FDA on April 11, 2017 for tardive dyskinesia (TD), and the commercial launch occurred on May 1, 2017 with a field-based sales team of approximately 160 personnel. Net product sales were $116.6 milliona for 2017, and total revenues were $161.6 million including $45.0 million in milestones and license fees. The company reported a net loss of $142.5 million, or $1.62 per share, compared with a net loss of $141.1 million in 2016.
The company states it does not expect to be profitable for 2018, and expects revenue to increase, with higher operating expenses, general and administrative expenses and interest expense. The pipeline is led by elagolix, a GnRH antagonist partnered with AbbVie, for which AbbVie submitted an NDA for endometriosis in the third quarter of 2017 that was accepted for priority review with a PDUFA date in the second quarter of 2018. The company also lists INGREZZA for Tourette syndrome (Phase IIb, with top-line data expected in late 2018) and opicapone for Parkinson's disease, in-licensed from BIAL for a $30 millionb upfront fee.
The T-Forward Tourette study did not meet its pre-specified primary endpoint. At December 31, 2017, cash, cash equivalents and investments totaled $763.3 millionc, against $517.5 million of 2.25% convertible senior notes due 2024 issued in May 2017.
The company states its existing capital resources are sufficient to fund requirements for at least the next 12 months. The accumulated deficit was approximately $1.2 billiond.
02—Key points
Key Highlights
- INGREZZA (valbenazine) approved by the FDA on April 11, 2017 for tardive dyskinesia; commercial launch May 1, 2017 with a specialty sales force of approximately 160 personnel.
- Net product sales of $116.6 million in 2017, with total revenues of $161.6 million including $45.0 million in milestones and license fees.
- Net loss of $142.5 million, or $1.62 per share, in 2017, compared with $141.1 million, or $1.63 per share, in 2016.
- Research and development expense rose to $121.8 million, including the $30 million upfront fee paid to BIAL for opicapone; sales, general and administrative expense rose to $169.9 million, driven by the INGREZZA launch.
- Elagolix (with AbbVie) NDA for endometriosis accepted for priority review with a PDUFA date in the second quarter of 2018, generating a $30.0 million milestone payment.
- Issued $517.5 million of 2.25% convertible senior notes due 2024 in May 2017; cash, cash equivalents and investments totaled $763.3 million at December 31, 2017.
- The company does not expect to be profitable in 2018, and the T-Forward Tourette study did not meet its pre-specified primary endpoint.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2017, Neurocrine Biosciences lost $0.88.
- Revenue$161.6M100.0%
- Cost of revenue−$1.3M0.8%
- Gross profit$160.4M99.2%
- Operating costs−$291.7M180.5%
- Operating income−$131.4M81.3%
- Interest, other & tax−$11.2M6.9%
- Net income−$142.5M88.2%
04—Financials
Financial Highlights
Figures from 10-KFY2017filed February 13, 2018Financial Statements
FY2017 against FY2016
| Line item | FY2017FY2016 | Change |
|---|---|---|
| Revenue | $161.63M$15.00M | +977.5% |
| Cost of Revenue | $1.25M$0 | — |
| Gross Profit | $160.37M$15.00M | +969.1% |
| R&D Expenses | $121.83M$94.29M | +29.2% |
| SG&A Expenses | $169.91M$68.08M | +149.6% |
| Operating Expenses | $292.99M$162.37M | +80.4% |
| Operating Income | -$131.36M-$147.37M | +10.9% |
| Interest Expense | $19.52M$0 | — |
| Net Income | -$142.54M-$141.09M | −1.0% |
| EPS (Basic) | $-1.62$-1.63 | +0.6% |
| EPS (Diluted) | $-1.62$-1.63 | +0.6% |
| Shares Outstanding (Basic) | 88.09M86.71M | +1.6% |
| Shares Outstanding (Diluted) | 88.09M86.71M | +1.6% |
05—Questions
Frequently Asked Questions
How much revenue did INGREZZA generate in its first year on the market?
Net product sales of INGREZZA were $116.6 million for the year ended December 31, 2017, following its commercial launch in late April 2017. The company recorded no similar product sales in 2016 or 2015.
Is Neurocrine Biosciences expected to become profitable soon?
No. The company states that it does not expect to be profitable for the year ending December 31, 2018. It expects higher operating expenses, higher general and administrative expenses and significantly higher interest expense in 2018, although it anticipates significantly higher sales and increased revenue.
What is the status of elagolix and when could it be approved?
AbbVie submitted an NDA for elagolix for endometriosis in the third quarter of 2017. The FDA accepted it for priority review with a PDUFA date in the second quarter of 2018. AbbVie also expects initial top-line data from the uterine fibroids Phase III program in the first quarter of 2018, with a potential NDA submission in 2019.
How is the company funded, and does it have debt?
At December 31, 2017, cash, cash equivalents and investments totaled $763.3 million. The company issued $517.5 million of 2.25% convertible senior notes due May 2024, with net proceeds of approximately $502.8 million. The company believes its existing capital resources will be sufficient for at least the next 12 months.
What risks did the T-Forward Tourette study present for INGREZZA's development?
The T-Forward study showed a significant improvement in overall symptoms as measured by the Clinical Global Impression of Change (p=0.015), but the pre-specified primary endpoint, the change from baseline in the Yale Global Tic Severity Scale at week 8, was not met (p=0.18). The company is now running the Phase IIb T-Force GOLD study, with top-line data expected in late 2018.
06—Continue